Develops gene control therapies for cancer and monogenic diseases, focusing on gene regulation and transcriptional control.
Syros Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a dynamic biopharmaceutical firm dedicated to pioneering treatments for cancer and monogenic diseases through innovative gene control medicines. Founded in 2011 as LS22, Inc. and rebranded in August 2012, Syros Pharmaceuticals focuses on advancing a diverse pipeline of therapeutic candidates.
The company's flagship products include Tamibarotene, an agonist of the selective retinoic acid receptor alpha, currently undergoing Phase III clinical trials for a genomically defined subset of patients with myelodysplastic syndrome and Phase II trials for acute myeloid leukemia. Additionally, SY-2101, a novel oral formulation of arsenic trioxide, shows promise for treating acute promyelocytic leukemia, while SY-5609, a cyclin-dependent kinase 7 inhibitor, is in Phase I trials targeting select advanced solid tumors.
Syros Pharmaceuticals leverages strategic collaborations such as its partnership with Incyte Corporation for target discovery in myeloproliferative neoplasms. Furthermore, a licensing agreement with TMRC Co. Ltd. underscores its commitment to the development and commercialization of Tamibarotene, enhancing its global reach and therapeutic impact in oncology and beyond.